RESUMO
Serum IgE levels have been documented in patients of acute type B hepatitis. There are very few studies on serum IgE in acute type A hepatitis and, to our knowledge, there are no data on serum IgE in acute delta hepatitis patients. The purpose of this study was to measure total IgE levels in 38 patients with acute A, B and delta hepatitis and in 181 controls in order to determine the possible existence of changes in this parameter in the course of these infections. Our results showed a relevant increase in IgE levels in the three groups (hepatitis A, B and delta) with respect to the control group. Moreover, the hepatitis B group showed increased total serum IgE levels with respect to the hepatitis delta group.
Assuntos
Hepatite A/imunologia , Hepatite B/imunologia , Hepatite D/imunologia , Imunoglobulina E/análise , Imunoglobulina E/metabolismo , Doença Aguda , Adulto , Idoso , Criança , Feminino , Hepatite A/sangue , Hepatite B/sangue , Hepatite D/sangue , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
The standardisation of allergenic extracts in micrograms of the major allergen has encouraged the search for new treatment schedules, with the purpose of shortening the number of visits and doses required to reach the maintenance dose without eliciting a greater risk of adverse reactions for the patients. With this objective, a prospective multicentre pharmacovigilance study was designed that included 200 patient with allergic rhinoconjunctivitis and/or allergic asthma sensitised to mites (Dermatophagoides pteronyssinu and/or farinae). The dose increment period was carried out using a cluster schedule, where the optimal dose wa reached after 4 visits, administering two doses in each visit. The duration of the study was 5 months and a total o 1902 doses were administered. At the end of the trial, 31 adverse reactions in 23 patients were recorded. Six of these were systemic (0.3% of t administered doses) recorded in 6 patients (3% of the sample). One was an immediate reaction (grade 1) and delayed (4 mild and 1 moderate). Two were asthmatic exacerbations, 2 cutaneous reactions, 1 rhinitis and 1 an unspecific symptom (not IgE-mediated). Two appeared upon administration of the first vial and the remaining 4 after administration of the third cluster. Therefore, the schedule tested presents an adequate tolerance profile, suggesting savings (compared to th conventional schedule of 13 doses per patient) of 1800 visits and 1000 treatment doses in the whole study.
Assuntos
Antígenos de Dermatophagoides/farmacologia , Asma/terapia , Dessensibilização Imunológica/métodos , Rinite Alérgica Perene/terapia , Adolescente , Adulto , Antígenos de Dermatophagoides/imunologia , Asma/imunologia , Criança , Análise por Conglomerados , Intervalos de Confiança , Relação Dose-Resposta Imunológica , Esquema de Medicação , Feminino , Seguimentos , Humanos , Imunoterapia/métodos , Masculino , Probabilidade , Estudos Prospectivos , Rinite Alérgica Perene/imunologia , Sensibilidade e EspecificidadeRESUMO
This trial has demonstrated that S.C.G. is significantly better than placebo and therefore that a 2% solution of S.C.G. is effective in the treatment of perennial rhinitis. It would appear that better results can be obtained in patients who have a demonstrable allergic aetiology with a nasal eosinophilia.
Assuntos
Cromolina Sódica/uso terapêutico , Rinite/tratamento farmacológico , Administração Intranasal , Adolescente , Adulto , Criança , Ensaios Clínicos como Assunto , Cromolina Sódica/administração & dosagem , Avaliação de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Placebos , Rinite Alérgica Sazonal/tratamento farmacológicoRESUMO
Thirty patients suffering from perennial allergic rhinitis took astemizole and cetirizine, 10 mg/d, under double-blind, crossover randomized conditions for 4 weeks. Four weeks washout separated the two periods. Nasal condition was improved, histamine and allergen-induced wheal responses were inhibited by both treatments with a slight advantage for cetirizine. Both treatments were well tolerated.
Assuntos
Benzimidazóis/uso terapêutico , Antagonistas dos Receptores Histamínicos H1/uso terapêutico , Hidroxizina/análogos & derivados , Rinite Alérgica Perene/tratamento farmacológico , Urticária/imunologia , Adulto , Astemizol , Cetirizina , Método Duplo-Cego , Humanos , Hidroxizina/uso terapêutico , Testes CutâneosRESUMO
BACKGROUND: Given the morbidity and mortality of asthma and the recent dramatic increase in its prevalence, pharmacologic prophylaxis of this disease in children at risk would represent a major medical advance. OBJECTIVES: The Preventia I Study was designed to evaluate the efficacy and long-term safety of loratadine in reducing the number of respiratory infections in children at 24 months. A secondary objective was to investigate the benefit of loratadine treatment in preventing the onset of respiratory exacerbations. METHODS: Preventia I was a randomized placebo-controlled study involving 22 countries worldwide. The children were 12-30 months of age at enrollment and had experienced at least five episodes of ENT infections, and no more than two episodes of wheezing during the previous 12 months. Phase I was a 12-month double-blind period during which the children were treated with loratadine 5 mg/day (2.5 mg/day for children=24 months of age) or placebo. Phase II was a double-blind follow-up period without study medication. RESULTS: Of the 412 children enrolled, 342 and 310 completed Phase I and Phase II, respectively. The results showed a significant decrease in the number of infections in the whole population of children. However, no difference was observed between the loratadine and placebo group. When considering secondary end-points, loratadine was shown to reduce the number of respiratory exacerbations during the treatment phase. None of the 204 children who received loratadine discontinued the study because of drug-related events. Loratadine treatment was not more sedative than placebo and was not associated with cardiovascular events. CONCLUSION: The strong decrease in the rate of infections in the children at risk of recurrent infections, while not being influenced by loratadine treatment, should encourage future reflection in terms of prophylactic management. This study also confirms the long-term safety of loratadine and its metabolites in young children.